Abstract 2597
Background
Cancer holds a huge psychosocial impact. Understanding the diagnosis and treatment gives cancer patients a feeling of autonomy and self-control. The patients’ perspective and expectations on the qualities of a medical oncologist are still poorly known.
Methods
Observational cross-sectional study of cancer patients observed in a Portuguese peripheral hospital in October 2018. When patients knew the primary tumour site, stage of disease and intent of treatment they were considered to have “Full knowledge”. Descriptive statistics and univariate analysis were performed, considering a CI of 95%.
Results
Seventy-two patients were included. Most were men (56.9%), with a median age of 60 years and 65.3% had an ECOG PS of 1. Patients reported feelings of shock (43.0%), sadness (38.9%), fear (34.7%) and courage (33.3%) when they became aware of their oncological diagnosis. About 12.5% of patients needed evaluation by Psychology/Psychiatry on the first 3 months after diagnosis, of which 2/3 had a history of depressive or anxiety disorders. The majority of patients (78%) received the diagnosis in a consultation, 12.5% in the emergency department with 4.2% being informed by their relatives (4.2%). About 90% of patients stated they knew their diagnosis while 5.6% were not sure. Correct identification of the primary tumour site occurred in 87% of patients and 81.9% knew the disease stage. Of those under treatment (n = 58), almost 20% did not understand its intention. About 54% of patients had "full knowledge" of the disease and treatments. There was no significant correlation between socio-demographic and clinical variables and "full knowledge" of the disease, and only age approached the significance level (p = 0.083). Patients mostly valued kindness (62.5%), honesty (55.6%) and knowledge (47.2%) in a medical oncologist.
Conclusions
Despite the majority of patients claiming to be aware of their disease, almost half did not understand the disease stage or treatment intention. Clear communication can contribute to a greater sense of knowledge, autonomy and adaptation to the disease, potentially influencing quality of life.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3020 - Circulating tumor DNA (ctDNA) analysis depicts mechanisms of resistance and tumor response to BRAF inhibitors in BRAF-mutant non-small cell lung cancer (NSCLC)
Presenter: Sandra Ortiz - Cuaran
Session: Poster Display session 1
Resources:
Abstract
1271 - A large scale prospective concordance study of oncogene driver detection between plasma- and tissue-based NGS analysis in advanced non-small cell lung cancer (NSCLC).
Presenter: Ryo Itotani
Session: Poster Display session 1
Resources:
Abstract
1132 - Biomarker status as a mediator of age-related overall survival (OS) in advanced non-small cell lung cancer (aNSCLC)
Presenter: Aaron Cohen
Session: Poster Display session 1
Resources:
Abstract
1502 - An exploratory analysis of on-treatment ctDNA measurement as a potential surrogate for overall survival for atezolizumab benefit in the OAK Study
Presenter: David Gandara
Session: Poster Display session 1
Resources:
Abstract
3912 - Disease monitoring of EGFR mutation-positive NSCLC patients via circulating tumor DNA
Presenter: Wei Fang Hsu
Session: Poster Display session 1
Resources:
Abstract
3856 - Incidence of T790M in NSCLC patients progressed to gefitinib, erlotinib, and afatinib: a study on circulating tumor DNA
Presenter: Romano Danesi
Session: Poster Display session 1
Resources:
Abstract
1330 - Folate receptor-positive circulating tumor cells as a predictive biomarker for the efficacy of first-line pemetrexed-based therapy in patients with non-squamous non-small cell lung cancer
Presenter: Xiaoxia Chen
Session: Poster Display session 1
Resources:
Abstract
3512 - Carcinoembryonic Antigen of Cerebrospinal Fluid Predict Prognosis of Leptomeningeal Metastasis from Non-Small Cell Lung Cancer
Presenter: Junjie Zhen
Session: Poster Display session 1
Resources:
Abstract
3852 - Liquid biopsy in clinical pratice of Non-Small-Cell-Lung Cancer (NSCLC): a multi-institutional experience
Presenter: Giovanna De Maglio
Session: Poster Display session 1
Resources:
Abstract
1205 - A Phase III Study Comparing SB8, a Proposed Bevacizumab Biosimilar, and Reference Bevacizumab in Patients with Metastatic or Recurrent Non-squamous NSCLC
Presenter: Martin Reck
Session: Poster Display session 1
Resources:
Abstract